Value of Serum Markers in Evaluating the Curative Effect of Immune Checkpoint Inhibitors for Lung Cancer
Clinical Laboratory · 2025
DOI: 10.7754/clin.lab.2024.240432 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Laboratory, 2025. Verfasst von Yan Chen und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Lung Neoplasms, Immune Checkpoint Inhibitors, Biomarkers, Tumor.
Abstract (Originalsprache)
BACKGROUND: In recent years, immune checkpoint inhibitors (ICIs) have been widely used in the treatment of lung cancer, and they significantly improve the survival rate of patients. However, the benefit rate of ICIs immunotherapy for lung cancer patients is only 15 - 40%. It is necessary to find effective and reliable biomarkers for evaluating the curative effect to achieve accurate immunotherapy for lung cancer. Therefore, the objective of this study was to analyze the value of response evaluation through detecting serum neuron-specific enolase (NSE), pro-gastrin-releasing peptide (pro-GRP), cytokeratin 19 fragment (Cyfra21-1), squamous cell carcinoma antigen (SCC), and carcinoembryonic antigen (CEA) in the lung cancer patients treated with ICIs. METHODS: The levels of serum NSE, pro-GRP, Cyfra21-1, SCC, and CEA in the lung cancer patients of pre- and post-immunotherapy with ICIs were detected by flow fluorescence method. RESULTS: The serum levels of NSE, pro-GRP, Cyfra21-1, SCC, and CEA in the patients with partial remission were decreased after ICIs immunotherapy of 2 cycles, and the difference was statistically significant (p 0.05). The sensitivities of NSE, pro-GRP, Cyfra21-1, SCC, and CEA in evaluating the efficacy of immunotherapy were 92.3%, 84.6%, 95.4%, 96.7%, and 81.3%. CONCLUSIONS: The changed levels of serum NSE, pro-GRP, Cyfra21-1, SCC, and CEA in the lung cancer patients in pre- and post-immunotherapy with ICIs were related to the therapeutic effect and may be used for the response evaluation. The SCLC patients should choose serum NSE, pro-GRP, and CEA for the response evaluation of ICIs immunotherapy, and the NSCLC patients should choose serum Cyfra21-1, SCC, and CEA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Chen, Y., Wu, E., Ma, Y., & Shi, G. (2025). Value of Serum Markers in Evaluating the Curative Effect of Immune Checkpoint Inhibitors for Lung Cancer. Clinical Laboratory. https://doi.org/10.7754/clin.lab.2024.240432
Vancouver
Chen Y, Wu E, Ma Y, Shi G. Value of Serum Markers in Evaluating the Curative Effect of Immune Checkpoint Inhibitors for Lung Cancer. Clinical Laboratory. 2025. doi:10.7754/clin.lab.2024.240432
BibTeX
@article{Chen2025,
author = {Chen, Yan and Wu, Endong and Ma, Yifeng and Shi, Guangli},
title = {Value of Serum Markers in Evaluating the Curative Effect of Immune Checkpoint Inhibitors for Lung Cancer},
journal = {Clinical Laboratory},
year = {2025},
doi = {10.7754/clin.lab.2024.240432}
}
EUVIMED